-
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
Tuesday, April 3, 2018 - 8:14am | 1646Read More...The biotech space wasn't immune to the broader market sell-off in March, although the degree of negativity was less pronounced among defensive biotech stocks. Rising demand for drugs, as the population ages, the prospects of the FDA expediting approval process as the Trump administration...
-
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Wednesday, September 28, 2016 - 10:02am | 364Read More...Amgen, Inc. (NASDAQ: AMGN) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating on the company, while lowering the price target from $206 to $198. Disappointing Data...
-
Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging
Friday, August 5, 2016 - 2:25pm | 392Read More...Deutsche Bank has downgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to Sell from Hold on valuation. Despite acknowledging the long-term potential of Ligand's "more than 150 shots-on-goal," the brokerage sees downside in shares over the next one year if there is lag in revenue momentum and lack...
-
Stephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017
Wednesday, April 13, 2016 - 9:33am | 519Read More...Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a unique biotech play that offers long-term staged growth profile, according to a note from Stephens, which initiated coverage of the stock with an Overweight (Volatile) rating. The brokerage has $150 price target on the stock, representing an upside of...
-
Biotechs With Upcoming PDUFA Dates
Wednesday, July 18, 2012 - 3:09pm | 871Read More...On Tuesday, the FDA approved the second weight-loss drug in the last 13 years when it green-lighted Vivus' drug Qsymia. On Wednesday, VVUS shares have shot up more than 14 percent to $30.27. The approval of this drug and the excitement that it has created in the biotech investing community may...
-
UPDATE: Morgan Stanley Upgrades Onyx Pharmaceuticals
Thursday, June 21, 2012 - 1:22pm | 149Read More...Morgan Stanley has upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Underweight to Equal-weight and has removed its $39 price target based on a high probability for the approval of Kyprolis. In the report, Morgan Stanley writes, "Central to our cautious thesis was the lack of compelling positive...
